{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:59:46Z","timestamp":1790740786962,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council of Australia","doi-asserted-by":"publisher","award":["1112125"],"award-info":[{"award-number":["1112125"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.exer.2019.05.020","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:49:06Z","timestamp":1558612146000},"page":"107680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"special_numbering":"C","title":["The renin-angiotensin-aldosterone system and its therapeutic targets"],"prefix":"10.1016","volume":"186","author":[{"given":"Katrina M.","family":"Mirabito Colafella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique M.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H. Jan","family":"Danser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.05.020_bib1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.exer.2019.05.020_bib3","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1161\/01.CIR.0000128696.12245.57","article-title":"Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries","volume":"109","author":"Batenburg","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100954","article-title":"Combined renin inhibition\/(pro)renin receptor blockade in diabetic retinopathy--a study in transgenic (mREN2)27 rats","volume":"9","author":"Batenburg","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.05.020_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1055\/a-0633-8892","article-title":"Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment","volume":"39","author":"Becker","year":"2018","journal-title":"Int. J. Sports Med."},{"key":"10.1016\/j.exer.2019.05.020_bib6","doi-asserted-by":"crossref","first-page":"8917578","DOI":"10.1155\/2016\/8917578","article-title":"Update on RAAS modulation for the treatment of diabetic cardiovascular disease","volume":"2016","author":"Bernardi","year":"2016","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.exer.2019.05.020_bib7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.exer.2019.05.020_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","article-title":"Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors","volume":"121","author":"Bosnyak","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.exer.2019.05.020_bib9","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.05.020_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.exer.2019.05.020_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1042\/CS20140776","article-title":"Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats","volume":"129","author":"Brouwers","year":"2015","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.exer.2019.05.020_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/01.HYP.22.4.513","article-title":"Nephrectomy, converting enzyme inhibition, and angiotensin peptides","volume":"22","author":"Campbell","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib13","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2019.05.020_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of Lisinopril in insulin-dependent diabetes mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2019.05.020_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joco.2016.09.009","article-title":"Therapeutic targets of renin-angiotensin system in ocular disorders","volume":"29","author":"Choudhary","year":"2017","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.exer.2019.05.020_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/CS20150939","article-title":"Epochs in the depressor\/pressor balance of the renin-angiotensin system","volume":"130","author":"Colafella","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.exer.2019.05.020_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.exer.2019.05.020_bib18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1357-2725(02)00178-4","article-title":"Local renin-angiotensin systems: the unanswered questions","volume":"35","author":"Danser","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.exer.2019.05.020_bib19","first-page":"1008","article-title":"Angiotensin levels in the eye","volume":"35","author":"Danser","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.05.020_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.HYP.24.1.37","article-title":"Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis","volume":"24","author":"Danser","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.96.1.220","article-title":"Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding","volume":"96","author":"Danser","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/01.HYP.0000186329.92187.2e","article-title":"Renin, prorenin and the putative (pro)renin receptor","volume":"46","author":"Danser","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.exer.2019.05.020_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/00004872-200105000-00017","article-title":"Angiotensin-converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of isolated perfused rat heart","volume":"19","author":"de Lannoy","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1590\/1414-431x20154583","article-title":"Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina","volume":"48","author":"Foureaux","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH13-06-0448","article-title":"Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques","volume":"111","author":"Fraga-Silva","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.exer.2019.05.020_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/ajh\/hpu044","article-title":"Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure","volume":"27","author":"Gao","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib28","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2019.05.020_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.exer.2019.05.020_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.exer.2019.05.020_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2017.07.008","article-title":"AT2 receptors in cardiovascular and renal diseases","volume":"125","author":"Kaschina","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCRESAHA.116.308384","article-title":"AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension","volume":"119","author":"Kemp","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.exer.2019.05.020_bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.104.515106","article-title":"Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness","volume":"112","author":"Klotz","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib36","article-title":"Adipocytes do not significantly contribute to plasma angiotensinogen","volume":"17","author":"Koizumi","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"key":"10.1016\/j.exer.2019.05.020_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.exer.2019.05.020_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.exer.2019.05.020_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib40","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1073\/pnas.83.13.4769","article-title":"Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process","volume":"83","author":"Kurtz","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2019.05.020_bib41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors","volume":"99","author":"Liu","year":"1997","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.exer.2019.05.020_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib43","first-page":"795452","article-title":"Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats","author":"Marques","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FJC.0000000000000208","article-title":"AT2 receptor activities and pathophysiological implications","volume":"65","author":"Matavelli","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.exer.2019.05.020_bib45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2011121159","article-title":"Liver angiotensinogen is the primary source of renal angiotensin II","volume":"23","author":"Matsusaka","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.exer.2019.05.020_bib46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.05.020_bib47","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000127112.36796.9B","article-title":"Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway","volume":"109","author":"Michel","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib48","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/db10-0552","article-title":"Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function","volume":"59","author":"Miller","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2019.05.020_bib49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199002000-00015","article-title":"Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition","volume":"15","author":"Mooser","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.exer.2019.05.020_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0002-9440(10)63806-0","article-title":"The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies","volume":"162","author":"Moravski","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2019.05.020_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.peptides.2014.10.005","article-title":"The role of renin-angiotensin system modulation on treatment and prevention of liver diseases","volume":"62","author":"Moreira de Macedo","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.exer.2019.05.020_bib52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db09-1218","article-title":"Human recombinant ACE2 reduces the progression of diabetic nephropathy","volume":"59","author":"Oudit","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2019.05.020_bib54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib55","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 Axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.exer.2019.05.020_bib56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.05.020_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.05.020_bib58","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.exer.2019.05.020_bib59","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1167\/iovs.16-20289","article-title":"Beneficial effects of combined AT1 receptor\/neprilysin inhibition (ARNI) versus AT1 receptor blockade alone in the diabetic eye","volume":"57","author":"Prasad","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.05.020_bib60","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1167\/iovs.14-13883","article-title":"Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice","volume":"55","author":"Qiu","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.05.020_bib61","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.05.020_bib63","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/HYPERTENSIONAHA.108.114322","article-title":"Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function","volume":"52","author":"Rentzsch","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.exer.2019.05.020_bib65","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/angiotensin-(1-7)\/mas receptor Axis: evidence from basic and clinical research","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.exer.2019.05.020_bib66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2019.05.020_bib67","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","article-title":"Angiotensin-(1-7)","volume":"63","author":"Santos","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00109-013-1087-0","article-title":"Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats","volume":"92","author":"Santos","year":"2014","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.exer.2019.05.020_bib69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/hy0202.103002","article-title":"Prorenin-induced myocyte proliferation","volume":"39","author":"Saris","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone 'escape' vs 'breakthrough'","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.exer.2019.05.020_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11906-010-0091-9","article-title":"The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point","volume":"12","author":"Sica","year":"2010","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.exer.2019.05.020_bib72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.exer.2019.05.020_bib73","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1097\/01.hjh.0000523257.57873.95","article-title":"Successful completion of a phase I, randomized, double-blind, placebo controlled, single ascending dose trial for the first in class Angiotensin At2-receptor agonist compound 21","volume":"35","author":"Steckelings","year":"2017","journal-title":"J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib74","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib75","first-page":"827","article-title":"Future drug discovery in renin-angiotensin-aldosterone system intervention","volume":"12","author":"Tamargo","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.exer.2019.05.020_bib76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.ATV.0000051875.41849.25","article-title":"ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency?","volume":"23","author":"Tom","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.exer.2019.05.020_bib77","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/CCM.0b013e3181c03009","article-title":"Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets","volume":"38","author":"Treml","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.exer.2019.05.020_bib78","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angioteninsogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib79","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/HJH.0b013e32833d01ae","article-title":"Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats","volume":"28","author":"van Esch","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib80","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.HYP.0000151323.93372.f5","article-title":"Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction","volume":"45","author":"van Esch","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib81","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.amjhyper.2005.02.005","article-title":"Adrenal angiotensin: origin and site of generation","volume":"18","author":"van Kats","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib82","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.102.13.1556","article-title":"Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II","volume":"102","author":"van Kats","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib83","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1046\/j.1523-1755.2001.00049.x","article-title":"Intrarenal angiotensin II: interstitial and cellular levels and site of production","volume":"60","author":"van Kats","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.exer.2019.05.020_bib84","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/HYPERTENSIONAHA.112.196022","article-title":"Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism","volume":"60","author":"Verdonk","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib85","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/HYPERTENSIONAHA.115.05267","article-title":"Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression","volume":"65","author":"Verdonk","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib86","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.exer.2019.05.020_bib87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjo.80.2.159","article-title":"Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system","volume":"80","author":"Wagner","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.05.020_bib88","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","article-title":"Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist","volume":"47","author":"Wan","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.exer.2019.05.020_bib89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","article-title":"Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis","volume":"3","author":"Wang","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.exer.2019.05.020_bib90","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fphar.2017.00564","article-title":"Anti-fibrotic potential of AT2 receptor agonists","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.exer.2019.05.020_bib91","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1161\/01.CIR.99.19.2583","article-title":"Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo","volume":"99","author":"Wei","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.05.020_bib92","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1007\/s00125-011-2239-9","article-title":"Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat","volume":"54","author":"Wilkinson-Berka","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.exer.2019.05.020_bib93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjhyper.2006.09.018","article-title":"Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina","volume":"20","author":"Wilkinson-Berka","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.exer.2019.05.020_bib94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1152\/advan.00177.2016","article-title":"The renal and cardiovascular effects of natriuretic peptides","volume":"41","author":"Wong","year":"2017","journal-title":"Adv. Physiol. Educ."},{"key":"10.1016\/j.exer.2019.05.020_bib95","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.exer.2019.05.020_bib96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/ATVBAHA.118.311817","article-title":"Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report","volume":"39","author":"Ye","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.exer.2019.05.020_bib97","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.exer.2019.05.020_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2019.05.020_bib99","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.exer.2019.05.020_bib100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41467-018-08125-6","article-title":"Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.exer.2019.05.020_bib101","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.exer.2019.05.020_bib102","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.110.955369","article-title":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction","volume":"122","author":"Zhong","year":"2010","journal-title":"Circulation"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519301575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483519301575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:28:54Z","timestamp":1762147734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483519301575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":102,"alternative-id":["S0014483519301575"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.05.020","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The renin-angiotensin-aldosterone system and its therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107680"}}